I guess that $25 million wasn’t for more product
Post# of 151638

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, stated, “...This infusion of capital will help ensure we have sufficient quantities of leronlimab available upon any potential approvals for COVID-19 treatment.”
...and everyone here fell for it. Again.

